|
gptkbp:instanceOf
|
gptkb:drug
triptan
|
|
gptkbp:approvalYear
|
1997
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N02CC03
|
|
gptkbp:bioavailability
|
40%
|
|
gptkbp:brand
|
Zomig
Zomig Rapimelt
Zomig-ZMT
|
|
gptkbp:CASNumber
|
139264-17-8
|
|
gptkbp:contraindication
|
ischemic heart disease
uncontrolled hypertension
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:drugClass
|
antimigraine agent
|
|
gptkbp:eliminationHalfLife
|
3 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
1992
|
|
gptkbp:form
|
gptkb:tablet
nasal spray
orodispersible tablet
|
|
gptkbp:genericName
|
yes
|
|
gptkbp:hasMolecularFormula
|
C16H21N3O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zolmitriptan
|
|
gptkbp:KEGGID
|
D08667
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
serotonin 5-HT1B/1D receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2013
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
25%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL123
5531
5735
DB00933
|
|
gptkbp:routeOfAdministration
|
oral
nasal
orodispersible tablet
|
|
gptkbp:sideEffect
|
nausea
dizziness
dry mouth
somnolence
|
|
gptkbp:synonym
|
311C90
Zomig
|
|
gptkbp:UNII
|
4K6D6G1A8V
|
|
gptkbp:usedFor
|
migraine
cluster headache
|
|
gptkbp:bfsParent
|
gptkb:Triptans
|
|
gptkbp:bfsLayer
|
7
|